Table 3.
Effect of treatment on haematological profile of adjuvant-induced arthritic rats
| WBC (×103/μL) | RBC (× 106/μL) | HGB (g dL−1) | HCT (%) | ESR (mm/h) | ||
|---|---|---|---|---|---|---|
| Control | IFA | 13.58 ± 1.25 | 8.18 ± 0.14 | 15.15 ± 0.22 | 47.15 ± 0.79 | 0.40 ± 0.24 |
| CFA untreated | 18.94 ± 0.85 | 6.83 ± 0.395 | 12.96 ± 0.25 | 40.26 ± 1.33 | 10.00 ± 1.87 | |
| Prophylactic | Dexamethasone | 7.00 ± 0.56¥ | 8.31 ± 0.18 | 14.74 ± 0.25 | 45.34 ± 0.97# | 2.20 ± 0.94# |
| HFE (50 mg/kg) | 16.65 ± 1.8 | 7.81 ± 0.14 | 13.85 ± 0.18 | 42.38 ± 0.86 | 6.50 ± 1.19 | |
| HFE (200 mg/kg) | 14.68 ± 0.2* | 8.08 ± 0.22 | 14.80 ± 0.37 | 45.35 ± 0.87** | 3.40 ± 0.93¥ | |
| HFE (500 mg/kg) | 13.97 ± 1.32** | 8.29 ± 0.26 | 14.96 ± 0.11 | 46.24 ± 0.27¥ | 1.60 ± 0.68¥ | |
| Therapeutic | Dexamethasone | 15.50 ± 1.61 | 8.76 ± 0.22 | 15.48 ± 0.42 | 48.33 ± 1.62 | 2.10 ± 0.10¥ |
| HFE (50 mg/kg) | 18.78 ± 0.75 | 7.86 ± 0.39 | 14.83 ± 0.44 | 43.93 ± 2.22 | 6.40 ± 0.81 | |
| HFE (200 mg/kg) | 17.55 ± 1.14 | 7.94 ± 0.10 | 14.33 ± 0.24 | 44.43 ± 0.44* | 4.00 ± 0.55¥ | |
| HFE (500 mg/kg) | 15.50 ± 0.39 | 8.19 ± 0.21 | 15.45 ± 0.57 | 47.00 ± 0.35¥ | 2.20 ± 0.37¥ | |
Sprague-Dawley rats were injected sub plantar with 0.1 ml of IFA or CFA into the right hind paw. The drug vehicle, dexamethasone (0.3 mg/kg) and HFE (50, 200, 500 mg/kg) were administered orally 1 h before arthritis induction and thereafter until the 28th day in the prophylactic approach and started on the 14th day after the induction of arthritis and daily till the 28th day in the therapeutic approach. Blood was collected from the tail vein on day 28 and a full blood count was done. Erythrocyte sedimentation rate (ESR) was determined using the standard Westergren method. Data presented show mean ± S.E.M for n ≥ 5. * (P ≤ 0.05), ** (P ≤ 0.01), # (P ≤ 0.001), ¥ (P ≤ 0.0001) values significantly different when compared with CFA arthritic control